Are the conclusions of Z11 relevant to community practice?
Identifieur interne : 007006 ( Ncbi/Checkpoint ); précédent : 007005; suivant : 007007Are the conclusions of Z11 relevant to community practice?
Auteurs : Guy C. Jones [États-Unis] ; Tuo Dong ; Charles B. Simone [États-Unis] ; Susan Stinson [États-Unis]Source :
- Clinical breast cancer [ 1526-8209 ] ; 2015.
Abstract
Findings of the ACOSOG Z11 trial have proven controversial, leaving physicians divided over which patients with positive sentinel lymph nodes (+SLNs) benefit from axillary lymph node dissection (ALND). Our institution reviewed our own experience with Z11-eligible patients who did not undergo ALND and explored factors that predict for +LNs on ALND following 1–2 +SLNs to determine which patients benefit from adjuvant therapy.
All breast cancer pathology reports from our institution containing the word “sentinel” between 7/1998 and 12/2001 were reviewed. We obtained follow-up information on patients meeting Z11 eligibility criteria that did not undergo ALND. We also compared pathological characteristics between patients with 1–2 +SLNs and +LNs on ALND to those with no further +LNs.
Of the 432 pathology reports reviewed, 38 were from patients meeting Z11-criteria that did not undergo ALND. At a median follow-up of 11.9yr, these patients had 5yr overall survival (OS) of 93.3% and 10yr OS of 79.3%. No patient had recurrent disease in the axilla. Of the 80 patients with 1–2 +SLNs who underwent ALND, tumors with +LNs on ALND were generally larger, non-ductal histology, more likely to be ER+, and PR+, and less likely to be Her2+.
Our institution’s 5yr OS (93.3%) for Z11-eligible patients closely resembled those from the Z11 trial (92.5%) and our 10yr data provide evidence of what to expect for Z11-enrolled patients on continued follow-up. Larger tumor, non-ductal, ER+, PR+, and Her2- were predictive for further +LNs on ALND which may reflect surgical bias.
Url:
DOI: 10.1016/j.clbc.2014.12.013
PubMed: 25659905
PubMed Central: 4495009
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 003432
- to stream Pmc, to step Curation: 003431
- to stream Pmc, to step Checkpoint: 001498
- to stream Ncbi, to step Merge: 007006
- to stream Ncbi, to step Curation: 007006
Links to Exploration step
PMC:4495009Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Are the conclusions of Z11 relevant to community practice?</title>
<author><name sortKey="Jones, Guy C" sort="Jones, Guy C" uniqKey="Jones G" first="Guy C." last="Jones">Guy C. Jones</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Dong, Tuo" sort="Dong, Tuo" uniqKey="Dong T" first="Tuo" last="Dong">Tuo Dong</name>
<affiliation><nlm:aff id="A2">Howard University College of Medicine, 2041 Georgia Avenue, Washington, D.C. 20060</nlm:aff>
<wicri:noCountry code="subfield">D.C. 20060</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Simone, Charles B" sort="Simone, Charles B" uniqKey="Simone C" first="Charles B." last="Simone">Charles B. Simone</name>
<affiliation wicri:level="2"><nlm:aff id="A3">Department of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Stinson, Susan" sort="Stinson, Susan" uniqKey="Stinson S" first="Susan" last="Stinson">Susan Stinson</name>
<affiliation wicri:level="2"><nlm:aff id="A4">Department of Radiation Oncology, Suburban Hospital, Johns Hopkins Medicine, 6420 Rockledge Dr Suite 1200, Bethesda, MD 20817</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Department of Radiation Oncology, Suburban Hospital, Johns Hopkins Medicine, 6420 Rockledge Dr Suite 1200, Bethesda</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25659905</idno>
<idno type="pmc">4495009</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495009</idno>
<idno type="RBID">PMC:4495009</idno>
<idno type="doi">10.1016/j.clbc.2014.12.013</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">003432</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003432</idno>
<idno type="wicri:Area/Pmc/Curation">003431</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003431</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001498</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001498</idno>
<idno type="wicri:Area/Ncbi/Merge">007006</idno>
<idno type="wicri:Area/Ncbi/Curation">007006</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">007006</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Are the conclusions of Z11 relevant to community practice?</title>
<author><name sortKey="Jones, Guy C" sort="Jones, Guy C" uniqKey="Jones G" first="Guy C." last="Jones">Guy C. Jones</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Dong, Tuo" sort="Dong, Tuo" uniqKey="Dong T" first="Tuo" last="Dong">Tuo Dong</name>
<affiliation><nlm:aff id="A2">Howard University College of Medicine, 2041 Georgia Avenue, Washington, D.C. 20060</nlm:aff>
<wicri:noCountry code="subfield">D.C. 20060</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Simone, Charles B" sort="Simone, Charles B" uniqKey="Simone C" first="Charles B." last="Simone">Charles B. Simone</name>
<affiliation wicri:level="2"><nlm:aff id="A3">Department of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Stinson, Susan" sort="Stinson, Susan" uniqKey="Stinson S" first="Susan" last="Stinson">Susan Stinson</name>
<affiliation wicri:level="2"><nlm:aff id="A4">Department of Radiation Oncology, Suburban Hospital, Johns Hopkins Medicine, 6420 Rockledge Dr Suite 1200, Bethesda, MD 20817</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Department of Radiation Oncology, Suburban Hospital, Johns Hopkins Medicine, 6420 Rockledge Dr Suite 1200, Bethesda</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical breast cancer</title>
<idno type="ISSN">1526-8209</idno>
<idno type="eISSN">1938-0666</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title>
<p id="P1">Findings of the ACOSOG Z11 trial have proven controversial, leaving physicians divided over which patients with positive sentinel lymph nodes (+SLNs) benefit from axillary lymph node dissection (ALND). Our institution reviewed our own experience with Z11-eligible patients who did not undergo ALND and explored factors that predict for +LNs on ALND following 1–2 +SLNs to determine which patients benefit from adjuvant therapy.</p>
</sec>
<sec id="S2"><title>Materials and Methods</title>
<p id="P2">All breast cancer pathology reports from our institution containing the word “sentinel” between 7/1998 and 12/2001 were reviewed. We obtained follow-up information on patients meeting Z11 eligibility criteria that did not undergo ALND. We also compared pathological characteristics between patients with 1–2 +SLNs and +LNs on ALND to those with no further +LNs.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">Of the 432 pathology reports reviewed, 38 were from patients meeting Z11-criteria that did not undergo ALND. At a median follow-up of 11.9yr, these patients had 5yr overall survival (OS) of 93.3% and 10yr OS of 79.3%. No patient had recurrent disease in the axilla. Of the 80 patients with 1–2 +SLNs who underwent ALND, tumors with +LNs on ALND were generally larger, non-ductal histology, more likely to be ER+, and PR+, and less likely to be Her2+.</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">Our institution’s 5yr OS (93.3%) for Z11-eligible patients closely resembled those from the Z11 trial (92.5%) and our 10yr data provide evidence of what to expect for Z11-enrolled patients on continued follow-up. Larger tumor, non-ductal, ER+, PR+, and Her2- were predictive for further +LNs on ALND which may reflect surgical bias.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
<li>Pennsylvanie</li>
</region>
</list>
<tree><noCountry><name sortKey="Dong, Tuo" sort="Dong, Tuo" uniqKey="Dong T" first="Tuo" last="Dong">Tuo Dong</name>
</noCountry>
<country name="États-Unis"><region name="Maryland"><name sortKey="Jones, Guy C" sort="Jones, Guy C" uniqKey="Jones G" first="Guy C." last="Jones">Guy C. Jones</name>
</region>
<name sortKey="Simone, Charles B" sort="Simone, Charles B" uniqKey="Simone C" first="Charles B." last="Simone">Charles B. Simone</name>
<name sortKey="Stinson, Susan" sort="Stinson, Susan" uniqKey="Stinson S" first="Susan" last="Stinson">Susan Stinson</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007006 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 007006 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Checkpoint |type= RBID |clé= PMC:4495009 |texte= Are the conclusions of Z11 relevant to community practice? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:25659905" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |